Castleark Management LLC reduced its stake in shares of Sarepta Therapeutics Inc (NASDAQ:SRPT) by 0.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 282,810 shares of the biotechnology company’s stock after selling 1,220 shares during the period. Castleark Management LLC owned 0.44% of Sarepta Therapeutics worth $15,736,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Sarepta Therapeutics by 39.5% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,448 shares of the biotechnology company’s stock valued at $192,000 after buying an additional 977 shares in the last quarter. Ladenburg Thalmann Financial Services Inc. raised its holdings in Sarepta Therapeutics by 140.9% during the third quarter. Ladenburg Thalmann Financial Services Inc. now owns 4,262 shares of the biotechnology company’s stock valued at $193,000 after buying an additional 2,493 shares in the last quarter. Prentiss Smith & Co. Inc. bought a new position in Sarepta Therapeutics during the fourth quarter valued at about $199,000. Brighton Jones LLC bought a new position in Sarepta Therapeutics during the third quarter valued at about $211,000. Finally, Arrowstreet Capital Limited Partnership acquired a new stake in shares of Sarepta Therapeutics in the fourth quarter valued at about $217,000. Institutional investors own 85.14% of the company’s stock.
Several equities research analysts have recently issued reports on SRPT shares. Zacks Investment Research downgraded Sarepta Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, January 5th. HC Wainwright started coverage on Sarepta Therapeutics in a research report on Friday, December 1st. They issued a “buy” rating and a $75.00 price target on the stock. BidaskClub raised Sarepta Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, January 13th. Royal Bank of Canada started coverage on Sarepta Therapeutics in a research report on Monday, January 22nd. They issued an “outperform” rating on the stock. Finally, UBS reaffirmed an “outperform” rating and issued a $56.51 price target (down from $76.00) on shares of Sarepta Therapeutics in a research report on Wednesday, December 27th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $75.31.
Shares of Sarepta Therapeutics Inc (NASDAQ SRPT) opened at $80.92 on Friday. Sarepta Therapeutics Inc has a 1 year low of $28.14 and a 1 year high of $84.37. The firm has a market capitalization of $5,250.00, a PE ratio of -101.15 and a beta of 1.51. The company has a debt-to-equity ratio of 0.54, a quick ratio of 12.96 and a current ratio of 13.91.
Sarepta Therapeutics (NASDAQ:SRPT) last released its earnings results on Thursday, March 1st. The biotechnology company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.05). Sarepta Therapeutics had a negative return on equity of 30.59% and a negative net margin of 32.79%. The firm had revenue of $57.30 million for the quarter, compared to analyst estimates of $57.33 million. During the same period last year, the business earned ($0.71) earnings per share. The firm’s quarterly revenue was up 961.1% compared to the same quarter last year. analysts anticipate that Sarepta Therapeutics Inc will post -1.18 EPS for the current year.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.